Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Induced Hypothermia · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Induced Hypothermia | PROCEDURE | Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours |
Inclusion Criteria: * have a severe traumatic brain injury as defined by either a GCS ≤ 8 and an abnormal CT scan (intracranial hemorrhage, cerebral edema or diffuse axonal injury) or a motor score ≤ 3 and normal CT scan * are aged between 1 and 16 years * are mechanically ventilated Exclusion Cri...
Induced Hypothermia is being studied for the treatment of Traumatic Brain Injury. It is an investigational therapy currently in Phase 2 clinical development. The approach involves lowering body temperature to potentially reduce brain damage following injury. It is not yet approved by regulatory authorities and remains under investigation.
Pulmonx Corporation (NASDAQ: LUNG) is the developer of Induced Hypothermia for Traumatic Brain Injury. The company is conducting clinical research to evaluate the safety and efficacy of this therapy in patients with this condition.
Induced Hypothermia is in Phase 2 clinical development for Traumatic Brain Injury. It is an investigational therapy, meaning it has not been approved by regulatory agencies. A Phase 2 clinical trial has been completed to assess its effects in the target patient population.
Induced Hypothermia has been evaluated in one completed Phase 2 clinical trial, NCT00282269, titled "Hypothermia in Traumatic Brain Injury in Children (HiTBIC)." This study enrolled 50 participants with Traumatic Brain Injury and was conducted in Australia and New Zealand.
Induced Hypothermia refers to the deliberate lowering of body temperature for therapeutic purposes. In the context of Traumatic Brain Injury, it is being investigated as a neuroprotective strategy. The clinical trial NCT00282269 specifically studied this approach in children with the condition.